232 related articles for article (PubMed ID: 28430774)
1. Is nintedanib effective for idiopathic pulmonary fibrosis?
Jeldres A; Labarca G
Medwave; 2017 Apr; 17(Suppl2):e6918. PubMed ID: 28430774
[TBL] [Abstract][Full Text] [Related]
2. Nintedanib: A Review of Its Use in Patients with Idiopathic Pulmonary Fibrosis.
Keating GM
Drugs; 2015 Jul; 75(10):1131-40. PubMed ID: 26063212
[TBL] [Abstract][Full Text] [Related]
3. Nintedanib: a novel therapeutic approach for idiopathic pulmonary fibrosis.
Dimitroulis IA
Respir Care; 2014 Sep; 59(9):1450-5. PubMed ID: 24782550
[TBL] [Abstract][Full Text] [Related]
4. Design of the INPULSIS™ trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis.
Richeldi L; Cottin V; Flaherty KR; Kolb M; Inoue Y; Raghu G; Taniguchi H; Hansell DM; Nicholson AG; Le Maulf F; Stowasser S; Collard HR
Respir Med; 2014 Jul; 108(7):1023-30. PubMed ID: 24834811
[TBL] [Abstract][Full Text] [Related]
5. Is pirfenidone effective for idiopathic pulmonary fibrosis?
Jeldres A; Labarca G
Medwave; 2017 Jan; 17(Suppl1):e6843. PubMed ID: 28112713
[TBL] [Abstract][Full Text] [Related]
6. The safety and tolerability of nintedanib in the treatment of idiopathic pulmonary fibrosis.
Cottin V
Expert Opin Drug Saf; 2017 Jul; 16(7):857-865. PubMed ID: 28571476
[TBL] [Abstract][Full Text] [Related]
7. A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK.
Rinciog C; Watkins M; Chang S; Maher TM; LeReun C; Esser D; Diamantopoulos A
Pharmacoeconomics; 2017 Apr; 35(4):479-491. PubMed ID: 28039616
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.
Richeldi L; du Bois RM; Raghu G; Azuma A; Brown KK; Costabel U; Cottin V; Flaherty KR; Hansell DM; Inoue Y; Kim DS; Kolb M; Nicholson AG; Noble PW; Selman M; Taniguchi H; Brun M; Le Maulf F; Girard M; Stowasser S; Schlenker-Herceg R; Disse B; Collard HR;
N Engl J Med; 2014 May; 370(22):2071-82. PubMed ID: 24836310
[TBL] [Abstract][Full Text] [Related]
9. Nintedanib in idiopathic pulmonary fibrosis.
Woodcock HV; Maher TM
Drugs Today (Barc); 2015 Jun; 51(6):345-56. PubMed ID: 26261848
[TBL] [Abstract][Full Text] [Related]
10. Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis.
Corte T; Bonella F; Crestani B; Demedts MG; Richeldi L; Coeck C; Pelling K; Quaresma M; Lasky JA
Respir Res; 2015 Sep; 16():116. PubMed ID: 26400368
[TBL] [Abstract][Full Text] [Related]
11. Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib.
Woodcock HV; Molyneaux PL; Maher TM
Drug Des Devel Ther; 2013; 7():503-10. PubMed ID: 23818761
[TBL] [Abstract][Full Text] [Related]
12. Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS(®) trials.
Richeldi L; Cottin V; du Bois RM; Selman M; Kimura T; Bailes Z; Schlenker-Herceg R; Stowasser S; Brown KK
Respir Med; 2016 Apr; 113():74-9. PubMed ID: 26915984
[TBL] [Abstract][Full Text] [Related]
13. Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib.
Bonella F; Stowasser S; Wollin L
Drug Des Devel Ther; 2015; 9():6407-19. PubMed ID: 26715838
[TBL] [Abstract][Full Text] [Related]
14. Nintedanib: first global approval.
McCormack PL
Drugs; 2015 Jan; 75(1):129-39. PubMed ID: 25430078
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis.
Richeldi L; Costabel U; Selman M; Kim DS; Hansell DM; Nicholson AG; Brown KK; Flaherty KR; Noble PW; Raghu G; Brun M; Gupta A; Juhel N; Klüglich M; du Bois RM
N Engl J Med; 2011 Sep; 365(12):1079-87. PubMed ID: 21992121
[TBL] [Abstract][Full Text] [Related]
16. Nintedanib: from discovery to the clinic.
Roth GJ; Binder R; Colbatzky F; Dallinger C; Schlenker-Herceg R; Hilberg F; Wollin SL; Kaiser R
J Med Chem; 2015 Feb; 58(3):1053-63. PubMed ID: 25474320
[TBL] [Abstract][Full Text] [Related]
17. Nintedanib in the treatment of idiopathic pulmonary fibrosis.
Mazzei ME; Richeldi L; Collard HR
Ther Adv Respir Dis; 2015 Jun; 9(3):121-9. PubMed ID: 25862013
[TBL] [Abstract][Full Text] [Related]
18. Guidelines for the medical treatment of idiopathic pulmonary fibrosis.
Xaubet A; Molina-Molina M; Acosta O; Bollo E; Castillo D; Fernández-Fabrellas E; Rodríguez-Portal JA; Valenzuela C; Ancochea J
Arch Bronconeumol; 2017 May; 53(5):263-269. PubMed ID: 28292522
[TBL] [Abstract][Full Text] [Related]
19. Naloxegol oxalate, pirfenidone, and nintedanib.
Hussar DA; Jeon MM
J Am Pharm Assoc (2003); 2015; 55(4):461-3. PubMed ID: 26161491
[No Abstract] [Full Text] [Related]
20. Forced vital capacity in idiopathic pulmonary fibrosis--FDA review of pirfenidone and nintedanib.
Karimi-Shah BA; Chowdhury BA
N Engl J Med; 2015 Mar; 372(13):1189-91. PubMed ID: 25806913
[No Abstract] [Full Text] [Related]
[Next] [New Search]
